Their study in mouse tumor model revealed that VLP-OVAT effectively suppressed tumor growth through the promotion of CD4+, CD8+, and effector memory T cells (TEM cells) and the reduction of myeloid-derived suppressor cells (MDSCs) within tumor-infiltrating lymphocytes and spleenocytes [311]. This evidence concerns the gene CD8A and neoplasm.